The FDA cleared a blood test for diagnosis, which offers a less invasive alternative.
4 reports, 3 independent
Updated Sep 9
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA cleared a blood test for diagnosis, which offers a less invasive alternative.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The FDA advisory panel recommended approval for a blood test developed by Mammogen.Sub-event
FDA cleared a blood test developed by LabCorp/CSF for diagnosis.1 source
Test cleared by FDA and gained CE-marking access in Europe.1 source
Keep exploring
The entities involved
Related events
Coverage
Newest first; wire copies grouped- pjmedia.com
- newsweek.com
- PR NewswireLabcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -
- PR NewswireLabcorp Achieves IVDR CE-Marking for PGDx elio™ tissue complete in the EU First-and-only test of its kind approved under new European Union regulations expands access to personalized cancer care for